Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|Bone Metastases
Interventions: BIOLOGICAL: Zoledronic acid|DRUG: Zoledronic acid
Sponsor: Fudan University
Collaborators: Novartis